Study Finds Ozempic-like Drugs May Reduce Breast Cancer Risk by 30%
A recent study from the University of Pennsylvania's Perelman School of Medicine suggests that women taking GLP-1 medications, such as Ozempic, are 30% less likely to develop breast cancer. These drugs, primarily used for weight loss, have shown potential benefits beyond their intended use, including reducing the risk of obesity-related cancers. The study analyzed data from over 110,000 women aged 45 to 80, finding a significant correlation between GLP-1 drug use and a decreased incidence of breast cancer. While the findings are promising, they do not establish a direct causal link, prompting calls for further clinical trials to explore the potential of these medications as preventative treatments for high-risk women. 
